Tumor-Specific Epitope Identification via Differential Agretopic Index
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly chemotherapy, lack specificity, leading to side effects as they target normal tissues along with cancer cells due to their selective rather than specific approach, necessitating a method to identify tumor-specific epitopes for developing non-toxic, effective therapies.
Innovation Solution
A method involving sequencing cancer and healthy tissue RNA or DNA to identify differences, analyzing these differences to determine tumor-specific epitopes, and using the Differential Agretopic Index (DAI) to select epitopes for pharmaceutical compositions that can be administered to patients, potentially combined with adjuvants or immune-modulating agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy is used to treat cancer, then cancer cells are attacked, but normal tissues are also damaged leading to side effects
Solution Approach 1:
The patent segments the cancer treatment approach by identifying and targeting specific tumor epitopes that are unique to cancer cells. Instead of using broad-spectrum chemotherapy that affects all rapidly dividing cells, the invention divides the problem into identifying cancer-specific antigens and creating targeted immunotherapies against those specific targets, thereby sparing normal tissues from damage
Solution Approach 2:
The patent applies local quality by creating immunotherapies with specific affinity for tumor epitopes. The immune response is localized to recognize and attack only cells expressing the specific tumor-associated antigens, rather than causing systemic damage to all normal tissues. This is achieved through personalized vaccine development based on the patient's specific tumor mutations
2Adaptability or versatility
If selective chemotherapy is used instead of specific targeting, then treatment can be applied broadly, but it attacks both cancer and normal cells
Solution Approach 1:
The patent changes the fundamental parameter of cancer treatment from non-specific chemical agents to specific immunological recognition. By sequencing tumor DNA to identify unique mutations and using those to create personalized epitope vaccines, the invention transforms treatment from a one-size-fits-all selective approach to a customized specific approach tailored to each patient's tumor genetics
Solution Approach 2:
The patent enables the patient's own immune system to perform the therapeutic function. By using the patient's tumor-derived epitopes to create a personalized vaccine, the body's immune system naturally recognizes and attacks cancer cells expressing those specific antigens, eliminating the need for external toxic chemotherapy agents
Data Source
AI summary
Described herein are methods of identifying tumor-specific epitopes from the cancer tissue DNA of cancer patients using both DNA sequencing and bioinformatics techniques. The identification of tumor-specific epitopes provides pharmaceutical compositions with a limited number of tumor-specific peptides suitable for personalized genomics-driven immunotherapy of human cancer. Specifically disclosed herein is a novel index called the Differential Agretopic Index (DAI) for the epitope which allows prediction of whether immunization with a particular epitope will be protective against the tumor. Pharmaceutical compositions and methods of administration are also included.